Related Experiment Videos
Sulbactam/ampicillin for treatment of polymicrobial pelvic infections
Abstract:
The increasing number of beta-lactam antibiotic-resistant bacteria observed in many strains of aerobic and anaerobic Gram-positive and Gram-negative bacteria, including Bacteroides species, has been well documented. Semisynthetic synthesis of penicillins and cephalosporins with increased resistance to beta-lactamase enzyme hydrolysis has not solved the problem. An alternative to therapy with newer agents is combination of an irreversible, suicide-type, beta-lactamase enzyme inhibitor such as sulbactam with a beta-lactam antibiotic such as ampicillin. Women with a variety of acute polymicrobial pelvic infections have been treated with the above combination, metronidazole or clindamycin combined with aminoglycoside, or cefoxitin in prospective trials. The clinical efficacy of 92.4%, in vitro bacteriological efficacy of 96.6%, and safety of sulbactam/ampicillin were comparable to that observed in women given comparative therapy. Penetration of pelvic tissues by sulbactam and ampicillin was excellent. Sulbactam/ampicillin is a viable alternative for the treatment of women with acute pelvic infections.
Insights
Sulbactam/ampicillin effectively treats acute pelvic infections in women. This combination shows high clinical and bacteriological efficacy, comparable to other treatments, and penetrates pelvic tissues well.
Area of Science:
- Microbiology
- Pharmacology
- Infectious Diseases
Background:
- Rising antibiotic resistance, particularly to beta-lactam antibiotics, poses a significant challenge in treating bacterial infections.
- Existing semisynthetic penicillins and cephalosporins have limited success against beta-lactamase producing bacteria.
- Bacteroides species are among the Gram-negative bacteria exhibiting increasing resistance.
Purpose of the Study:
- To evaluate the efficacy and safety of sulbactam/ampicillin for treating acute polymicrobial pelvic infections in women.
- To compare the outcomes of sulbactam/ampicillin therapy with established treatments like metronidazole, clindamycin/aminoglycoside, and cefoxitin.
Main Methods:
- Prospective clinical trials were conducted to assess treatment outcomes.
- In vitro and clinical efficacy rates were determined for sulbactam/ampicillin.
- Tissue penetration of sulbactam and ampicillin was evaluated.
Main Results:
- Sulbactam/ampicillin demonstrated a clinical efficacy of 92.4% and an in vitro bacteriological efficacy of 96.6%.
- The safety and efficacy profiles were comparable to those of comparative therapies.
- Excellent penetration of pelvic tissues by both sulbactam and ampicillin was observed.
Conclusions:
- Sulbactam/ampicillin is a safe and effective treatment option for acute pelvic infections in women.
- The combination offers a viable alternative to existing therapies, addressing challenges posed by antibiotic resistance.
- High efficacy and excellent tissue penetration support its use in clinical practice.